Cancer Res Treat.  2006 Jun;38(3):144-151.

AKAP12alpha is Associated with Promoter Methylation in Lung Cancer

• Jo U
• Whang YM
• Kim HK
• Kim YH

Abstract

PURPOSE: Promoter methylation is an important mechanism for silencing tumor-suppressor genes in cancer and it is a promising tool for the development of molecular biomarkers. The purpose of the present study was to investigate whether inactivation of the A Kinase Anchoring Protein 12 (AKAP12) gene is associated with promoter methylation in lung cancer.
MATERIALS AND METHODS
The AKAP12 expression was examined by reverse transcription-polymerase chain reaction (RT-PCR) in ten lung cancer cell lines. The methylation status of the AKAP12alpha promoter was analyzed by performing bisulfite sequencing analysis in ten lung cancer cell lines, twenty four lung tissues and matched normal tissues.
RESULTS
The AKAP12alpha expression was reduced in 6 of 10 (60%) lung cancer cell lines, whereas the AKAP12beta expression was absent in 1 of 10 (10%) lung cancer cell lines. The AKAP12alpha expression was restored after treatment with the demethylating agent 5-aza-2'-deoxycytidine in three lung cancer cell lines. Methylation of CpG island 1 in the AKAP12alpha promoter was detected in 30% of the lung cancer cell lines, whereas methylation of CpG island 2 in the AKAP12alpha promoter was observed in the immortalized bronchial cell line and in all the lung cancer cell lines. In lung tumors, the CpG island 1 in the AKAP12alpha promoter was infrequently methylated. However, CpG island 2 in the AKAP12alpha promoter was highly methylated in lung tumors compared with the surrounding normal tissues, and this was statistically significant (p=0.0001).
CONCLUSION
Our results suggest that inactivation of the AKAP12alpha expression is associated with DNA methylation of the promoter region in lung cancer, and that AKAP12alpha may play an important role in lung cancer carcinogenesis.

Keyword

Promoter methylation; Lung neoplasms; AKAP12alpha

MeSH Terms

Biomarkers
Carcinogenesis
Cell Line
CpG Islands
DNA Methylation
Lung Neoplasms*
Lung*
Methylation*
Phosphotransferases
Promoter Regions, Genetic
Phosphotransferases

Figure

• 

  Fig. 1 Expression profiles of the AKAP12 gene in lung cancer cell lines.

• 

  Fig. 2 The restoration of the AKAP12α expression by 5-aza-2'-deoxycytidin.

• 

  Fig. 3 A map of the CpG islands of the AKAP12α gene spanning 1 kb upstream of the transcription start site. The 5' region of the AKAP12α gene contains two large CpG islands 1 and 2 (gray area), which encompass a putative promoter region.

• 

  Fig. 4 Methylation status of the AKAP12α promoter in lung cancer cell lines. (A) The frequency of CpG island 1 methylation for each sample is indicated by the methylatied CpG site/total CpG sites (%). (B) The frequency of CpG island 2 methylation for each sample is indicated bymethylated CpG site/total CpG sites (%).

• 

  Fig. 5 Methylation status of the AKAP12α promoter in lung cancer tissues and the matched normal tissues. (A) The frequency of CpG island 1 methylation for each sample is indicated by methylated CpG site/total CpG sites (%). (B) The frequency of CpG island 1 methylation for each sample is indicated by methylated CpG site/total CpG sites (%). p-value (p<0.05) computed from a paired sample t-test.

• 

  Fig. 6 Percentage of methylated USF binding sites in CpG island 2 of the AKAP12α promoter. The frequency of methylation for each sample is indicated by the methylated USF binding site/total USF binding CpG sites (%).

Reference

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001; 37(Suppl 8):S4–S66. PMID: 11602373.

2. Kim HK. Lung cancer in Korea. Cancer Res Treat. 2002; 34:1–2.

3. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3:415–428. PMID: 12042769.

4. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003; 349:2042–2054. PMID: 14627790.

5. Doerfler W. DNA methylation and gene activity. Annu Rev Biochem. 1983; 52:93–124. PMID: 6311083.

6. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer. 2004; 4:707–717. PMID: 15343277.

7. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene. 2002; 21:5427–5440. PMID: 12154405.

8. Tsou JA, Hagen JA, Carpenter CL, Laird-Offringa IA. DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene. 2002; 21:5450–5461. PMID: 12154407.

9. Nauert JB, Klauck TM, Langeberg LK, Scott JD. Gravin, an autoantigen recognized by serum from myasthenia gravis patients, is a kinase scaffold protein. Curr Biol. 1997; 7:52–62. PMID: 9000000.

10. Lin X, Tombler E, Nelson PJ, Ross M, Gelman IH. A novel src- and ras-suppressed protein kinase C substrate associated with cytoskeletal architecture. J Biol Chem. 1996; 271:28430–28438. PMID: 8910468.

11. Streb JW, Kitchen CM, Gelman IH, Miano JM. Multiple promoters direct expression of three AKAP12 isoforms with distinct subcellular and tissue distribution profiles. J Biol Chem. 2004; 279:56014–56023. PMID: 15496411.

12. Streb JW, Miano JM. AKAP12alpha, an atypical serum response factor-dependent target gene. J Biol Chem. 2005; 280:4125–4134. PMID: 15590635.

13. Choi MC, Jong HS, Kim TY, Song SH, Lee DS, Lee JW, et al. AKAP12/Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity. Oncogene. 2004; 23:7095–7103. PMID: 15258566.

14. Kettunen E, Anttila S, Seppanen JK, Karjalainen A, Edgren H, Lindstrom I, et al. Differentially expressed genes in nonsmall cell lung cancer: expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet Cytogenet. 2004; 149:98–106. PMID: 15036884.

15. Wikman H, Kettunen E, Seppanen JK, Karjalainen A, Hollmen J, Anttila S, et al. Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array. Oncogene. 2002; 21:5804–5813. PMID: 12173052.

16. Bailey-Wilson JE, Amos CI, Pinney SM, Petersen GM, de Andrade M, Wiest JS, et al. A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am J Hum Genet. 2004; 75:460–474. PMID: 15272417.

17. Goffin J, Eisenhauer E. DNA methyltransferase inhibitors-state of the art. Ann Oncol. 2002; 13:1699–1716. PMID: 12419742.

18. Robertson KD. DNA methylation, methyltransferases, and cancer. Oncogene. 2001; 20:3139–3155. PMID: 11420731.

19. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, et al. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med. 1995; 1:686–692. PMID: 7585152.

20. Takai D, Jones PA. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci USA. 2002; 99:3740–3745. PMID: 11891299.

21. Streb JW, Miano JM. Cross-species sequence analysis reveals multiple charged residue-rich domains that regulate nuclear/cytoplasmic partitioning and membrane localization of a kinase anchoring protein 12 (SSeCKS/Gravin). J Biol Chem. 2005; 280:28007–28014. PMID: 15923193.

22. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol. 2004; 22:2790–2799. PMID: 15254046.

23. Ballestar E, Paz MF, Valle L, Wei S, Fraga MF, Espada J, et al. Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J. 2003; 22:6335–6345. PMID: 14633992.

24. Fujii G, Nakamura Y, Tsukamoto D, Ito M, Shiba T, Takamatsu N. CpG methylation at the USF-binding site is important for the liver-specific transcription of the chipmunk HP-27 gene. Biochem J. 2006; 395:203–209. PMID: 16396632.

25. Chang YS, Wang L, Suh YA, Mao L, Karpen SJ, Khuri FR, et al. Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer. Oncogene. 2004; 23:6569–6580. PMID: 15247904.